Recent Quotes
My Watchlist
Indicators
Star 60
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Disc Medicine, Inc. - Common Stock (NQ:IRON)

61.44 +1.40 (+2.33%)
Streaming Delayed Price Updated: 10:22 AM EDT, Mar 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Disc Medicine, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
IRON Investors Have Opportunity to Join Disc Medicine, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc. - IRON
From Pomerantz LLP
Via GlobeNewswire
News headline image
Disc Medicine CFO Sells $720k Worth of Shares Amid FDA Rejection ↗
This clinical-stage biopharmaceutical company recently had one of its treatments rejected for FDA approval. Now the company is cutting its workforce. 
Via The Motley Fool
Topics Regulatory Compliance
Disc Medicine, Sanofi, Eli Lilly Shares Slip On Reports Of FDA Increasing Review Time For Drugs Granted Priority Review Vouchers ↗
Via Stocktwits
News headline image
Disc Medicine Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
From Disc Medicine Inc
Via GlobeNewswire
News headline image
Disc Medicine Stock Is Swinging, but This Fund's New $52 Million Bet Shows Conviction ↗
Disc Medicine develops therapies for rare blood disorders, leveraging clinical-stage biotech expertise in red blood cell biology. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Apogee Therapeutics Stock Up 100% as Fund Lifts Stake to $28 Million ↗
This biotech specializes in monoclonal antibody therapies for inflammatory and immunological diseases with significant unmet needs. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Fund Bet $20 Million on RAPT Therapeutics as Stock Surges 500% This Past Year and Buyout Offer Emerges ↗
RAPT Therapeutics develops oral therapies for oncology and inflammatory diseases, with lead candidates progressing in clinical trials. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Disc Medicine Lands New $20 Million Investment as FDA Sets Up Potential Q4 Catalyst ↗
This clinical-stage biotech develops therapies targeting hematologic disorders, with a pipeline centered on red blood cell biology. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc.- IRON
From Pomerantz LLP
Via GlobeNewswire
News headline image
Disc Medicine to Participate in Upcoming Investor Conferences
From Disc Medicine Inc
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc.- IRON
From Pomerantz LLP
Via GlobeNewswire
News headline image
Disc Medicine Stock Slumps After FDA Declines Approval For Inherited Disorder Drug Over Efficacy Concerns ↗
The FDA said in a letter to the company published on Friday that the data submitted by the company is insufficient proof of clinical benefit for bitopertin. 
Via Stocktwits
News headline image
Disc Medicine Receives Complete Response Letter from FDA for Bitopertin for the Treatment of EPP
From Disc Medicine Inc
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc.- IRON
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Disc Medicine, Inc. – IRON
From Pomerantz LLP
Via GlobeNewswire
News headline image
Disc Medicine Appoints Lisa Amaya Price, MBA as Chief Human Resources Officer
From Disc Medicine Inc
Via GlobeNewswire
News headline image
Disc Medicine Highlights Recent Achievements and Key Business Objectives and Milestones for 2026
From Disc Medicine Inc
Via GlobeNewswire
News headline image
What Investors Should Know About a $511K Disc Medicine Insider Sale and a 26% Stock Run ↗
This clinical-stage biotech specializing in blood disorders reported a notable insider sale amid strong recent stock performance. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Disc Medicine to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Disc Medicine Inc
Via GlobeNewswire
News headline image
Disc Medicine Stock Slides After FDA Fast-Track Approval Doubts Surface — Wall Street Calls It An ‘Overreaction’ ↗
Stat News on Friday raised concerns for Biopertin’s expedited approval under the FDA Commissioner's National Priority Voucher program. 
Via Stocktwits
News headline image
Disc Medicine Presents Positive Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting
From Disc Medicine Inc
Via GlobeNewswire
News headline image
Portfolio Adjustment: Institutional Heavyweight Exits Biotech Stock ↗
Bain Capital completely exited its position in Disc Medicine stock during the third quarter 
Via The Motley Fool
News headline image
Disc Medicine Inc (NASDAQ:IRON) Reports Wider-Than-Expected Q3 2025 Loss Amid Pipeline Advancements ↗
Disc Medicine reported a wider Q3 2025 loss but advanced its bitopertin NDA with FDA priority review, targeting a 2025/2026 launch. 
Via Chartmill
News headline image
Disc Medicine Reports Third Quarter 2025 Financial Results and Provides Business Update
From Disc Medicine Inc
Via GlobeNewswire
News headline image
Disc Medicine Announces Presentation of Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting
From Disc Medicine Inc
Via GlobeNewswire
News headline image
Disc Medicine to Participate in Upcoming Investor Conferences
From Disc Medicine Inc
Via GlobeNewswire
News headline image
Disc Medicine Announces Pricing of $250 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants
From Disc Medicine Inc
Via GlobeNewswire
News headline image
Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
From Disc Medicine Inc
Via GlobeNewswire
News headline image
Disc Medicine Provides Update on Hematology Portfolio and Outlines Near-Term Business Objectives and Anticipated Milestones
From Disc Medicine Inc
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.